ActiveMSers Forums  

Go Back   ActiveMSers Forums > ActiveMSers.org Forums > Dave's SCT Journey

Reply
 
Thread Tools Display Modes
  #1  
Old 09-11-2019, 01:26 PM
ActiveMSers's Avatar
ActiveMSers ActiveMSers is online now
Dave @ ActiveMSers
 
Join Date: Jun 2008
Location: Albuquerque, NM
Posts: 3,719
Default Large study finds "AHSCT leads to a drug-free prolonged disease remission"

Efficacy of autologous Hematopoietic stem cell transplantation for MS. A single-centre report of 81 patients.

C. Zhukovsky1, A. Tolf1, H. Cherif2, K. Carlson2, J. Burman1 1Neurology, 2Haematology, Uppsala University, Uppsala, Sweden

Introduction: Autologous hematopoietic stem cell transplantation (AHSCT) has been used as a treatment of MS since 1995. The first patient in Sweden was treated in 2004 and in 2016 it was recommended as a treatment option for patients with active MS by the Swedish Board of Health and Welfare.

Objectives: To describe clinical outcomes after AHSCT for MS.

Methods: All patients who had been treated with AHSCT for MS at Uppsala University Hospital from April 2004 to February 2019 (n=81) were included in the study; 56 women and 25 men. Seventy-seven (95%) were diagnosed with relapsing-remitting MS. The median age was 29 years (range 8 - 58 years); the mean disease duration before AHSCT was 6.0 years (5.6 years); the median number of treatments prior to AHSCT was 2 (range 0 - 5); the mean annualized relapse rate in the year preceding AHSCT was 2.2 (2.1), and the median baseline EDSS was 3.5 (range 0 - 8.5). Nineteen patients were treated with the intermediate intensity BEAM/ATG (BCNU, etoposide, cytarabine and melphalan + anti-thymocyte globulin) conditioning regimen and 62 patients were treated with a low intensity cyclophosphamide/ATG conditioning regimen.

Results: The mean follow-up time was 3.9 years (3.2) and the total number of follow-up years was 314. Progression free survival was 93 % (95% CI, 85 - 100%): relapse free survival was 87% (95% CI, 78 - 97%); MRI event free survival was 74% (95% CI, 69 - 89%); and event free survival (no EDSS progression, no relapses and no new MRI lesions) was 68 % (95% CI, 54 - 84%) at five years. The annualized relapse rate post-AHSCT was 0.022. At end of follow-up, 62% of patients had improved in their expanded disability status scale (EDSS) score; 35% were unchanged and 3.3% worsened. The median ΔEDSS at 1, 2 and 3 years after AHSCT were 1.5 (range -1 - 8), 2 (range -1.5 - 8) and 2 (range -1.5 - 8.25). The overall mortality was 0 %.

Conclusion: AHSCT leads to a drug-free prolonged disease remission and functional improvement in a majority of patients.
__________________
Dave Bexfield
ActiveMSers
Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump


All times are GMT -4. The time now is 07:48 AM.


Powered by vBulletin® Version 3.7.0
Copyright ©2000 - 2019, Jelsoft Enterprises Ltd.
ActiveMSers